Personalis (Personalis) Cash, Cash Equivalents, Marketable Securities : $114.18 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Personalis Cash, Cash Equivalents, Marketable Securities?

Personalis's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($137.21 Mil) to Sep. 2023 ($120.66 Mil) but then stayed the same from Sep. 2023 ($120.66 Mil) to Dec. 2023 ($114.18 Mil).

Personalis's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($287.06 Mil) to Dec. 2022 ($167.66 Mil) and declined from Dec. 2022 ($167.66 Mil) to Dec. 2023 ($114.18 Mil).

Personalis Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Personalis's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Cash, Cash Equivalents, Marketable Securities Chart

Personalis Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

128.29

203.29

287.06

167.66

114.18

Personalis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															167.66	148.94	137.21	120.66	114.18

Personalis Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Personalis (NAS:PSNL) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Personalis Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Personalis's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Personalis (Personalis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

04X:Germany

Address

6600 Dumbarton Circle, Fremont, CA, USA, 94555

Website

https://www.personalis.com

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Executives

Richard Chen	officer: Chief Scientific Officer	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore	officer: General Counsel	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana	officer: Chief Financial Officer	400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall	officer: President	6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder	director	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff	director	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West	director, officer: President and CEO	C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom	director	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr	director	1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum	director
Arif Janmohamed	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025